A
Alcista
Alcista · 25%AQST
$2.66
Precio del escenario
$3.780
-0.261 (-6.90%)Al cierre
Loading chart…
- Máximo
- 4.100
- Apertura
- 4.090
- Precio medio ponderado por volumen
- 3.88
- Volumen
- 5.25M
- Capitalización
- 235.79M
- Mínimo
- 3.750
- Importe
- 20.36M
- EV/EBITDA, TTM
- -13.54
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Análisis de IA of Aquestive Therapeutics, Inc. (AQST)
MantenerCurrently, Aquestive Therapeutics Inc is not a strong buy due to its ongoing financial struggles and recent insider selling, despite some positive catalysts. The stock is priced at $4.78, with an RSI of 62.56 indicating it is nearing overbought territory. The forward P/E ratio is currently at 0, suggesting uncertainty about future earnings. However, the gross margin has improved significantly to 75.99% in Q1 2026, indicating potential for profitability if revenue continues to grow. The main risk is the legal investigation into the company, which could negatively impact investor sentiment and stock price.
Recomendaciones de analistas (4)
+138.10% de potencial alcista
Comprar
4 Comprar
0 Mantener
0 Vender
Actual: 3.78
Mínimo
6.00
Promedio
9.00
Máximo
12.00
Oppenheimer
Superar al mercado
$8
2026-04-24
Oppenheimer
2026-04-24
Precio objetivo
$8
Superar al mercado
Alliance Global
Comprar
$9
2026-03-05
Alliance Global
2026-03-05
Precio objetivo
$9
Comprar
Lake Street
Comprar
$6
2026-02-03
Lake Street
2026-02-03
Precio objetivo
$6
Comprar
Leerink
Superar al mercado
$4.29
2026-02-02
Leerink
2026-02-02
Precio objetivo
$4.29
Superar al mercado
Alliance Global
Comprar
$12
2026-02-02
Alliance Global
2026-02-02
Precio objetivo
$12
Comprar
Métricas de valoración
El PER previsto actual de Aquestive Therapeutics, Inc. (AQST) es 0.00, frente a su media de 5 años de -4.99.
Escenarios de precio de Alphio AI para AQST
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con AQST en cartera
Cronología de eventos
Noticias
8.510-15NewsfilterFDA Accepts Anaphylm Drug Application for Review
7.010-07PRnewswireLegal Investigation into Aquestive Therapeutics
- 8.509-22Newsfilter
Aquestive Resubmits NDA for Anaphylm Sublingual Film
9.009-17NASDAQ.COMAquestive Resubmits NDA for Anaphylm Sublingual Film
9.508-19NASDAQ.COMAquestive Therapeutics Q2 Earnings Report Analysis
Preguntas frecuentes sobre AQST, respondidas por Alphio AI
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, Aquestive Therapeutics Inc is not a strong buy due to its ongoing financial struggles and recent insider selling, despite some positive catalysts. The stock is priced at $4.78, with an RSI of 62.56 indicating it is nearing overbought territory. The forward P/E ratio is currently at 0, suggesting uncertainty about future earnings. However, the gross margin has improved significantly to 75.99% in Q1 2026, indicating potential for profitability if revenue continues to grow. The main risk is the legal investigation into the company, which could negatively impact investor sentiment and stock price.
4 analysts cover AQST: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.